Please enable JS

News & Publications

Other Publications and Programs

 

Technology

Maeder T. Sweet Medicines. 2002. Sci Am 287(1): 40-7.

Venkataraman G, Shriver Z, Raman R, and Sasisekharan R.. Sequencing Complex Polysaccharides. 1999. Science 286 (5439): 537-542.

He XA, Washburn N, Arevalo E, et al. Analytical characterization of IgG Fc subclass variants through high-resolution separation combined with multiple LC-MS identification. Analytical and Bioanalytical Chemistry 2015;407(23):7055-7066.

Sobolev O, Binda E, O'Farrell S, et al. Adjuvanted influenza-H1N1 vaccination reveals lymphoid signatures of age-dependent early responses and of clinical adverse events. Nature Immunology 2016;17:204–213.

Madsen JA, Yin Y, Qiao J, et al. Covalent labeling denaturation mass spectrometry for sensitive localized higher order structure comparisons. Analytical and Bioanalytical Chemistry 2016;88(4):2478–2488.

 

Posters

  • Toward the complete characterization of host cell proteins in biotherapeutics via affinity depletions, LC-MS/MS, and multivariate analysis   View Poster 
  • Combining measurements to estimate properties and characterization extent of complex biochemical mixtures; applications to Heparan Sulfate   View Poster 
  • Application of a Novel Computational Approach to Identify New Targets and Pathways for Therapeutic Intervention in Scleroderma, American College of Rheumatology Annual Meeting, Nov 5-6 2017.   View Poster 
  • Molecular Profiling of RA Patients Suggests a Differential Involvement of Adaptive and Innate Cell Populations in Response to Anti-TNF Treatment, American College of Rheumatology Annual Meeting, Nov 5-6 2017  View Poster 

 

Heparin

Sucharita Roy, Ahmed El Hadri, Sebastien Richard, Fanny Denis, Kimberly Holte, Jay Duffner, Fei Yu, Zoya Galcheva-Gargova, Ishan Capila, Birgit Schultes, Maurice Petitou, and Ganesh V. KaundinyaSynthesis and Biological Evaluation of a Unique Heparin Mimetic Hexasaccharide for Structure−Activity Relationship StudiesJournal of Medicinal Chemisty. 2014 Jun 12;57(11):4511-20

Kishimoto TK, Viswanathan K, Ganguly T, Elankumaran S, Smith S, Pelzer K, Lansing JC, Sriranganathan N, Zhao G, Galcheva-Gargova Z, Al-Hakim A, Bailey GS, Fraser B, Roy S, Rogers-Cotrone T, Buhse L, Whary M, Fox J, Nasr M, Dal Pan GJ, Shriver Z, Langer RS, Venkataraman G, Austen KF, Woodcock J and Sasisekharan R. Contaminated heparin associated with adverse clinical events and activation of the contact system. 2008. N Engl J Med 358(23): 2457-67. Epub 2008 Apr 23.

Guerrini M, Beccati D, Shriver Z, Naggi A, Viswanathan K, Bisio A, Capila I, Lansing JC, Guglieri S, Fraser B, Al-Hakim A, Gunay NS, Zhang Z, Robinson L, Buhse L, Nasr M, Woodcock J, Langer R, Venkataraman G, Linhardt RJ, Casu B, Torri G and Sasisekharan R. Oversulfated chondroitin sulfate is a contaminant in heparin associated with adverse clinical events. 2008. Nat Biotechnol 26(6): 669-75. Epub 2008 Apr 23.

 

Other Programs


Adomiparin

Rao SV, Melloni C, Myles-Dimauro S, Broderick S, Kosinski AS, Kleiman NS, Dzavík V, Tanguay JF, Chandna H, Gammon R, Rivera E, Alexander JH, Fier I,Roach J and Becker RC; EMINENCE Investigators. Evaluation of a new heparin agent in percutaneous coronary intervention: results of the phase 2evaluation of M118 IN pErcutaNeous Coronary intErvention (EMINENCE) Trial. 2010.Circulation 121(15): 1713-21. Epub 2010 Apr 5.

Sundaram M, Qi Y, Shriver Z, Liu D, Zhao G, Venkataraman G, Langer R and Sasisekharan R. Rational design of low-molecular weight heparins with improved invivo activity. 2003. Proc Natl Acad Sci USA 100(2): 651-6. Epub 2003 Jan 13.

 

Necuparanib (Study Discontinued) - Manuscripts

Amanda MacDonald, Michelle Priess, Jennifer Curran, Jamey Guess, Victor Farutin, Ilse Oosterom, Chia Lin Chu, Edward Cochran, Lynn Zhang, Kristen Getchell, Martijn Lolkema, Birgit C Schultes, and Silva Krause; Necuparanib, a multi-targeting heparan sulfate mimetic, targets tumor and stromal compartments in pancreatic cancer

O'Reilly EM, Roach J, Miller P, Yu KH, Tjan C, Rosano M, Krause S, Avery W, Wolf J, Flaherty K, Nix D, Ryan DP. Safety, Pharmacokinetics, Pharmacodynamics, and Antitumor Activity of Necuparanib Combined with Nab-Paclitaxel and Gemcitabine in Patients with Metastatic Pancreatic Cancer: Phase I Results. Oncologist. 2017 Dec;22(12):1429-e139. doi: 10.1634/theoncologist.2017-0472. Epub 2017 Nov 20.

Zhou H, Roy S, Cochran E, Zouaoui R, Chu CL, Duffner J, Zhao G, Smith S, Galcheva-Gargova Z, Karlgren J, Dussault N, Kwan RYQ, Moy E, Barnes M, Long A, Honan C, Qi YW, Shriver Z, Ganguly T, Schultes B, Venkataraman G and Kishimoto TK. M402, a Novel Heparan Sulfate Mimetic, Targets Multiple Pathways Implicated in Tumor Progression and Metastasis. 2011. PLoS One6(6): e21106. Epub 2011 Jun 16.

 

Necuparanib (Study Discontinued) - Posters

  • Safety, Pharmacokinetics, Pharmacodynamics, and Antitumor Activity of Necuparanib Combined with nab-Paclitaxel and Gemcitabine in Patients with Metastatic Pancreatic Cancer: Updated Phase 1 Results, ASCO 2016  View Poster 
  • Necuparanib Inhibits Pancreatic Cancer Progression and Invasion in a 3D Tumor and Stromal Cell Co-Culture System, AACR 2016  View Poster 
  • Safety, Pharmacokinetics, Pharmacodynamics, and Antitumor Activity of Necuparanib Combined withnab-Paclitaxel and Gemcitabine in Patients with Metastatic Pancreatic Cancer: Phase 1 Results, ASCO 2015  View Poster 
  • Necuparanib Affects Tumor Progression and Invasion in a 3D Co-Culture System of Pancreatic Cancer Cells and Stellate Cells, AACR 2015  View Poster
  • M402 Increases Gemcitabine Uptake into Pancreatic Tumors as a Result of Stromal Matrix Remodeling, GI Cancer Symposium 2014  View Poster
  • M402, a Novel Drug Candidate for Pancreatic Cancer: Efficacy in Animal Models and Initial Clinical Study Design, Cancer Advance 2013 View Poster

  • Inhibition of Heparan sulfate proteoglycans enhanced signaling in Pancreatic Ductal Adenocarcinoma reduces EMT, AACR 2013 View Poster
  • M402, a Heparan Sulfate Mimetic and Novel Candidate for the Treatment of Pancreatic Cancer View Poster
  • M402, a Heparan Sulfate Mimetic, Inhibits Tumor Revascularization and Invasiveness after High-Dose Taxane Treatment in a Mouse Breast Cancer Model  View Poster
  • M402, a Novel Heparan Sulfate Mimetic, Inhibits Pancreatic Tumor Growth and Desmoplasia Potentially via Shh Signaling in an Orthotopic Mouse Model  View Poster
  • M402 –A novel heparan sulfate proteoglycan mimetic targeting tumor-host interactions  View Poster
  • M402, a Novel Heparan Sulfate Mimetic, Synergizes with Gemcitabine to Improve Survival and Reduce Metastasis and Epithelial-to-Mesenchymal Transition (EMT) in a Genetically Engineered Mouse Model for Pancreatic Cancer  View Poster
  • M-ONC 402-a non anticoagulant low molecular weight heparin inhibits tumor metastasis  View Poster
  • M-ONC 402, A novel non-anticoagulant heparin, inhibits P-Selectin function and metastatic seeding of tumor cells in mice  View Poster

 

Last Updated 11/14/18